Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); Awaiting Approval of HIV-OTC Test

June 29, 2012 9:02 AM EDT Send to a Friend
Get Alerts OSUR Hot Sheet
Price: $4.43 +0.91%

Rating Summary:
    11 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 28 | New: 13
Trade OSUR Now!
Canaccord Genuity reiterates a 'Buy' on OraSure Technologies (NASDAQ: OSUR) price target of $14.00.

Analyst, Jeffrey Frelick, said, "Near--term approval likely for HIV--OTC. For a product that moved slowly through the early years of development, it has suddenly advanced rapidly in the past nine to 12 months. Based on the 180-day PMA clock that has been ticking since early January when OSUR filed, FDA approval could come as early as July 7; however, we think late summer is more likely."

For an analyst ratings summary and ratings history on OraSure Technologies click here. For more ratings news on OraSure Technologies click here.

Shares of OraSure Technologies closed at $10.32 yesterday, with a 52 week range of $6.29-$12.28.


Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here



You May Also Be Interested In


Related Categories

Analyst Comments

Related Entities

Canaccord Genuity

Add Your Comment